Time Sensitive

Ordering Recommendation

Monitor engraftment of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation.




Polymerase Chain Reaction/Fragment Analysis




5-9 days

New York DOH Approval Status

Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Specimen Required

Patient Preparation

Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A).

Specimen Preparation

Transport 3 mL whole blood. (Min: 2 mL) Increase the amount of blood submitted for patients with low cell counts.

Storage/Transport Temperature

Ambient. Also acceptable: refrigerated. Ship overnight. Specimens should be received within 24 hours of collection for optimal isolation of T cells.

Unacceptable Conditions

Clotted or hemolyzed specimens.


Please provide the results and date of the patient's most recent WBC and differential counts.


Room temperature: 72 hours; Refrigerated: 72 hours; Frozen: Unacceptable

Reference Interval

Type Maternal Maternal cells only.
Type Patient Patient cells only.
Mixed Patient and Maternalt cells present.  Semi-quantitative results of percentage of patient and maternal cells will be reported.

Interpretive Data

Background Information: for Maternal T Cell Engraftment in SCID
Indication: Severe combined immunodeficiency (SCID) patients lack T cells and cannot recognize and reject maternal T cells from maternal-fetal transfusion. Maternal T cells can proliferate in the absence of host T cells, leading to difficulty in determining the host T-cell numbers required for the diagnosis of SCID and/or can cause graft-versus-host disease (GVHD)-line presentation.
Methodology: PCR followed by capillary electrophoresis. Specimens are analyzed using 15 autosomal markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, THO1, D13S317, D16S539, D2S1338, D19S433, vWa, TPOX, D18S51, D5S818, and FGA) and one gender marker (amelogenin).
Limit of Detection: 2 percent of minor cell population.
Limitations: Diagnostic errors can occur due to rare sequence variations.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)


To complete Maternal T Cell Engraftment in SCID testing, samples should be collected to perform the following three tests: (1) A buccal swab or brush collected from the patient for Maternal T Cell Engraftment in SCID, Pre-Engraftment Specimen (ARUP test code 2014694), used as a genetic baseline for the patient. (2) A peripheral blood sample from the biological mother for Maternal T Cell Engraftment in SCID, Maternal Specimen (ARUP test code 2014704), used as a genetic baseline for the mother. (3) A peripheral blood sample collected from the patient for Maternal T Cell Engraftment in SCID (ARUP test code 2014699). T cells isolated from the blood sample will be genotyped for comparison to the patient and biological mother baseline genotypes. If T-cell sorting is not completed on the blood sample before submission of Maternal T Cell Engraftment in SCID (ARUP test code 2014699), BMT Cell Isolation (ARUP test code 2005498) will be added to each order of Maternal T Cell Engraftment in SCID (ARUP test code 20146990). Additional charges apply for cell isolation.

Hotline History


CPT Codes

81268; If cell sorting is performed, add 88184


Component Test Code* Component Chart Name LOINC
2014700 Specimen, Maternal Engraftment
2014701 Mat Engraftment, Informative Loci
2014702 Maternal Engraftment, Interpretation
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Maternal engraftment
  • SCID engraftment
Maternal T Cell Engraftment in SCID